메뉴 건너뛰기




Volumn 53, Issue 1, 2013, Pages 1-13

The pharmacology and therapeutic use of dabigatran etexilate

Author keywords

Cardiovascular; Clinical pharmacology; Clinical research; Clinical trials; Hematology; Pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; AMIODARONE; ANTIVITAMIN K; APIXABAN; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; CLARITHROMYCIN; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DICLOFENAC; DIGOXIN; DRONEDARONE; ENOXAPARIN; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR; QUINIDINE; RANITIDINE; RIFAMPICIN; RIVAROXABAN; THROMBIN INHIBITOR; VERAPAMIL; WARFARIN; XIMELAGATRAN;

EID: 84877862997     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011432169     Document Type: Review
Times cited : (26)

References (78)
  • 1
    • 33746833635 scopus 로고    scopus 로고
    • Acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation-Executive summary: A report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation
    • Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol . 2006;48(4):854-906.
    • (2006) J Am Coll Cardiol , vol.48 , Issue.4 , pp. 854-906
    • Fuster, V.1    Ryden, L.E.2    Cannom, D.S.3
  • 2
    • 0035832261 scopus 로고    scopus 로고
    • Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study
    • Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA . 2001;285(18):2370-2375.
    • (2001) JAMA , vol.285 , Issue.18 , pp. 2370-2375
    • Go, A.S.1    Hylek, E.M.2    Phillips, K.A.3
  • 3
    • 0028244264 scopus 로고
    • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
    • Investigators AF. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med . 1994;154(13): 1449-1457.
    • (1994) Arch Intern Med , vol.154 , Issue.13 , pp. 1449-1457
    • Investigators, A.F.1
  • 4
    • 0037221236 scopus 로고    scopus 로고
    • Atrial fibrillation is associated with severe acute ischemic stroke
    • Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology . 2003;22(2): 118-123.
    • (2003) Neuroepidemiology , vol.22 , Issue.2 , pp. 118-123
    • Dulli, D.A.1    Stanko, H.2    Levine, R.L.3
  • 5
    • 0036844470 scopus 로고    scopus 로고
    • Prediction of length of stay of first-ever ischemic stroke
    • Chang KC, Tseng MC, Weng HH, Lin YH, Liou CW, Tan TY. Prediction of length of stay of first-ever ischemic stroke. Stroke . 2002;33(11):2670-2674.
    • (2002) Stroke , vol.33 , Issue.11 , pp. 2670-2674
    • Chang, K.C.1    Tseng, M.C.2    Weng, H.H.3    Lin, Y.H.4    Liou, C.W.5    Tan, T.Y.6
  • 6
    • 11044231366 scopus 로고    scopus 로고
    • An economic model of stroke in atrial fibrillation: The cost of suboptimal oral anticoagulation
    • discussion S458-S461
    • Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care . 2004;10(14) (suppl):S451-S458; discussion S458-S461.
    • (2004) Am J Manag Care , vol.10 , Issue.14 SUPPL.
    • Caro, J.J.1
  • 7
    • 0028343127 scopus 로고
    • Risk factors for intracranial hemorrhage in outpatients taking warfarin
    • Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med . 1994;120(11): 897-902.
    • (1994) Ann Intern Med , vol.120 , Issue.11 , pp. 897-902
    • Hylek, E.M.1    Singer, D.E.2
  • 8
    • 4644230820 scopus 로고    scopus 로고
    • The pharmacology and management of the vitamin k antagonists: The seventh accp conference on antithrombotic and thrombolytic therapy
    • Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest . 2004;126(3)(suppl):204S-233S.
    • (2004) Chest , vol.126 , Issue.3 SUPPL.
    • Ansell, J.1    Hirsh, J.2    Poller, L.3    Bussey, H.4    Jacobson, A.5    Hylek, E.6
  • 9
    • 0037738891 scopus 로고    scopus 로고
    • Practical tips for warfarin dosing and monitoring
    • Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med . 2003;70(4):361-371.
    • (2003) Cleve Clin J Med , vol.70 , Issue.4 , pp. 361-371
    • Jaffer, A.1    Bragg, L.2
  • 10
    • 32644446621 scopus 로고    scopus 로고
    • The risk of hemorrhage among patients with warfarin-associated coagulopathy
    • Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol . 2006;47(4):804-808.
    • (2006) J Am Coll Cardiol , vol.47 , Issue.4 , pp. 804-808
    • Garcia, D.A.1    Regan, S.2    Crowther, M.3    Hylek, E.M.4
  • 11
    • 77953851760 scopus 로고    scopus 로고
    • Underuse of oral anticoagulants in atrial fibrillation: A systematic review
    • e634
    • Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med . 2010;123(7):638-645, e634.
    • (2010) Am J Med , vol.123 , Issue.7 , pp. 638-645
    • Ogilvie, I.M.1    Newton, N.2    Welner, S.A.3    Cowell, W.4    Lip, G.Y.5
  • 12
    • 65449163045 scopus 로고    scopus 로고
    • Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the united states
    • Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm . 2009;15(3):244-252.
    • (2009) J Manag Care Pharm , vol.15 , Issue.3 , pp. 244-252
    • Baker, W.L.1    Cios, D.A.2    Sander, S.D.3    Coleman, C.I.4
  • 13
    • 65649103773 scopus 로고    scopus 로고
    • Evaluating the impact of study-level factors on warfarin control in u.s.-based primary studies: A meta-analysis
    • Cios DA, Baker WL, Sander SD, Phung OJ, Coleman CI. Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis. Am J Health Syst Pharm . 2009;66(10):916-925.
    • (2009) Am J Health Syst Pharm , vol.66 , Issue.10 , pp. 916-925
    • Cios, D.A.1    Baker, W.L.2    Sander, S.D.3    Phung, O.J.4    Coleman, C.I.5
  • 14
    • 80052906902 scopus 로고    scopus 로고
    • Anticoagulation control in sweden: Reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry auricula
    • Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J . 2011;32(18):2282-2289.
    • (2011) Eur Heart J , vol.32 , Issue.18 , pp. 2282-2289
    • Wieloch, M.1    Sjalander, A.2    Frykman, V.3    Rosenqvist, M.4    Eriksson, N.5    Svensson, P.J.6
  • 15
    • 79953248796 scopus 로고    scopus 로고
    • 2011 Accfahahrs focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the american college of cardiology foundation/american heart association task force on practice guidelines
    • Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm . 2011;8(1):157-176.
    • (2011) Heart Rhythm , vol.8 , Issue.1 , pp. 157-176
    • Wann, L.S.1    Curtis, A.B.2    January, C.T.3
  • 16
    • 0346992348 scopus 로고    scopus 로고
    • Direct thrombin inhibitors for anticoagulation
    • Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother . 2004;38(1):99-109.
    • (2004) Ann Pharmacother , vol.38 , Issue.1 , pp. 99-109
    • Nutescu, E.A.1    Wittkowsky, A.K.2
  • 17
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med . 2009;361(12):1139-1151.
    • (2009) N Engl J Med , vol.361 , Issue.12 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 18
    • 79953066921 scopus 로고    scopus 로고
    • 2011 Accf/aha/hrs focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the american college of cardiology foundation/american heart association task force on practice guidelines
    • Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation . 2011;123(10):1144-1150.
    • (2011) Circulation , vol.123 , Issue.10 , pp. 1144-1150
    • Wann, L.S.1    Curtis, A.B.2    Ellenbogen, K.A.3
  • 19
    • 79952301326 scopus 로고    scopus 로고
    • Apixaban in patients with atrial fibrillation
    • Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med . 2011;364(9):806-817.
    • (2011) N Engl J Med , vol.364 , Issue.9 , pp. 806-817
    • Connolly, S.J.1    Eikelboom, J.2    Joyner, C.3
  • 20
    • 80052825103 scopus 로고    scopus 로고
    • Apixaban versus warfarin in patients with atrial fibrillation
    • Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 2011;365(11):981-992.
    • (2011) N Engl J Med , vol.365 , Issue.11 , pp. 981-992
    • Granger, C.B.1    Alexander, J.H.2    McMurray, J.J.3
  • 21
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med . 2011;365(10):883-891.
    • (2011) N Engl J Med , vol.365 , Issue.10 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 22
    • 84877841791 scopus 로고    scopus 로고
    • Bayer Pharma AG. FDA approves Xarelto (rivaroxaban tablets) for the prophylaxis of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery Accessed January 6
    • Bayer Pharma AG. FDA approves Xarelto (rivaroxaban tablets) for the prophylaxis of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery. 2011. http://www.press. bayer.com/baynews/baynews.nsf/id/FDA-Approves-Xarelto-rivaroxaban-tablets- Prophylaxis-Deep-Vein-Thrombosis-Which-May-Lead-a-Pulmonary. Accessed January 6, 2012.
    • (2011) , pp. 2012
  • 23
    • 45949095568 scopus 로고    scopus 로고
    • Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines (8th edition
    • Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest . 2008;133(6)(suppl):546S-592S.
    • (2008) Chest , vol.133 , Issue.6 SUPPL.
    • Singer, D.E.1    Albers, G.W.2    Dalen, J.E.3
  • 24
    • 0037171819 scopus 로고    scopus 로고
    • Structure-based design of novel potent nonpeptide thrombin inhibitors
    • Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem . 2002;45(9):1757-1766.
    • (2002) J Med Chem , vol.45 , Issue.9 , pp. 1757-1766
    • Hauel, N.H.1    Nar, H.2    Priepke, H.3    Ries, U.4    Stassen, J.M.5    Wienen, W.6
  • 25
    • 55549147508 scopus 로고    scopus 로고
    • Dabigatran etexilate: An oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases
    • Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy . 2008;28(11):1354-1373.
    • (2008) Pharmacotherapy , vol.28 , Issue.11 , pp. 1354-1373
    • Baetz, B.E.1    Spinler, S.A.2
  • 26
    • 34548031359 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    • Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol . 2007;64(3):292-303.
    • (2007) Br J Clin Pharmacol , vol.64 , Issue.3 , pp. 292-303
    • Stangier, J.1    Rathgen, K.2    Stahle, H.3    Gansser, D.4    Roth, W.5
  • 27
    • 84877851576 scopus 로고    scopus 로고
    • US Food and Drug Administration Clinical review for NDA 022-512 Pradaxa (dabigatran). Accessed January 6
    • US Food and Drug Administration. Clinical review for NDA 022-512 Pradaxa (dabigatran). http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugs AdvisoryCommittee/ucm226008.htm. Accessed January 6, 2012.
  • 28
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost . 2010;103(6):1116-1127.
    • (2010) Thromb Haemost , vol.103 , Issue.6 , pp. 1116-1127
    • Van Ryn, J.1    Stangier, J.2    Haertter, S.3
  • 29
    • 41949116970 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
    • Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet . 2008;47(5):285-295.
    • (2008) Clin Pharmacokinet , vol.47 , Issue.5 , pp. 285-295
    • Stangier, J.1
  • 30
    • 0022997648 scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of warfarin: Understanding the dose-effect relationship
    • Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet . 1986;11(6):483-504.
    • (1986) Clin Pharmacokinet , vol.11 , Issue.6 , pp. 483-504
    • Holford, N.H.1
  • 31
    • 59349098538 scopus 로고    scopus 로고
    • Coadministration of dabigatran etexilate and atorvastatin: Assessment of potential impact on pharmacokinetics and pharmacodynamics
    • Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs . 2009;9(1):59-68.
    • (2009) Am J Cardiovasc Drugs , vol.9 , Issue.1 , pp. 59-68
    • Stangier, J.1    Rathgen, K.2    Stahle, H.3    Reseski, K.4    Kornicke, T.5    Roth, W.6
  • 32
    • 84877859653 scopus 로고    scopus 로고
    • Pradaxa (dabigatran etexilate) [prescribing information]. Accessed January 6
    • Pradaxa (dabigatran etexilate) [prescribing information]. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.serdocBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed January 6, 2012.
    • (2012)
  • 33
    • 84877865472 scopus 로고    scopus 로고
    • Coumadin (warfarin) [prescribing information]. Accessed January 6
    • Coumadin (warfarin) [prescribing information]. http://www .accessdata.fda.gov/drugsatfda-docs/label/2010/009218s108lbl. pdf. Accessed January 6, 2012.
    • (2012)
  • 34
    • 19344366484 scopus 로고    scopus 로고
    • Systematic overview of warfarin and its drug and food interactions
    • Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med . 2005;165(10):1095-1106.
    • (2005) Arch Intern Med , vol.165 , Issue.10 , pp. 1095-1106
    • Holbrook, A.M.1    Pereira, J.A.2    Labiris, R.3
  • 35
    • 38749131205 scopus 로고    scopus 로고
    • The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    • Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos . 2008;36(2): 386-399.
    • (2008) Drug Metab Dispos , vol.36 , Issue.2 , pp. 386-399
    • Blech, S.1    Ebner, T.2    Ludwig-Schwellinger, E.3    Stangier, J.4    Roth, W.5
  • 36
    • 77956492689 scopus 로고    scopus 로고
    • The frequency of prescription of p-glycoprotein-affecting drugs in atrial fibrillation
    • Jungbauer L, Dobias C, Stollberger C, Weidinger F. The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost . 2010;8(9):2069-2070.
    • (2010) J Thromb Haemost , vol.8 , Issue.9 , pp. 2069-2070
    • Jungbauer, L.1    Dobias, C.2    Stollberger, C.3    Weidinger, F.4
  • 37
    • 84877849674 scopus 로고    scopus 로고
    • Pradaxa (dabigatran etexilate) [summary of product characteristics]. Accessed September 22
    • Pradaxa (dabigatran etexilate) [summary of product characteristics]. http://spaf.pradaxa.com/content/dam/internet/chc/pradaxa/com-COPY/documents/S mPC%20English%20version%20anx-104049-en-04Aug2011.pdf. Accessed September 22, 2011.
    • (2011)
  • 38
    • 84877871047 scopus 로고    scopus 로고
    • Pradax (dabigatran etexilate) [product monograph]. Accessed January 6
    • Pradax (dabigatran etexilate) [product monograph]. http://webprod3 .hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00013431. Accessed January 6, 2012.
    • (2012)
  • 39
    • 35348879239 scopus 로고    scopus 로고
    • Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (petro study
    • Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol . 2007;100(9):1419-1426.
    • (2007) Am J Cardiol , vol.100 , Issue.9 , pp. 1419-1426
    • Ezekowitz, M.D.1    Reilly, P.A.2    Nehmiz, G.3
  • 40
    • 77952792359 scopus 로고    scopus 로고
    • Abstract 4629: Long-term open label extension of the prevention of embolic and thrombic events on dabigatran in atrial fibrillation (petro-ex study
    • Nagarakanti R, Ezekowitz MD, Parcham-Azad K, et al. Abstract 4629: long-term open label extension of the prevention of embolic and thrombic events on dabigatran in atrial fibrillation (PETRO-Ex study). Circulation . 2008;118:S-922.
    • (2008) Circulation , vol.118
    • Nagarakanti, R.1    Ezekowitz, M.D.2    Parcham-Azad, K.3
  • 41
    • 84877859360 scopus 로고    scopus 로고
    • US Food and Drug Administration. January 6
    • US Food and Drug Administration. Addendum to the clinical review for NDA 022-512 Pradaxa (dabigatran). http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM226012.pdf. January 6, 2012.
    • (2012) Addendum to the Clinical Review for NDA 022-512 Pradaxa (dabigatran
  • 43
    • 77956977472 scopus 로고    scopus 로고
    • Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the re-ly trial
    • Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet . 2010;376(9745):975-983.
    • (2010) Lancet , vol.376 , Issue.9745 , pp. 975-983
    • Wallentin, L.1    Yusuf, S.2    Ezekowitz, M.D.3
  • 44
    • 78650114177 scopus 로고    scopus 로고
    • Dabigatran and warfarin in vitamin k antagonist-naive and-experienced cohorts with atrial fibrillation
    • Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and-experienced cohorts with atrial fibrillation. Circulation . 2010;122(22):2246-2253.
    • (2010) Circulation , vol.122 , Issue.22 , pp. 2246-2253
    • Ezekowitz, M.D.1    Wallentin, L.2    Connolly, S.J.3
  • 45
    • 0028244264 scopus 로고
    • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
    • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med . 1994;154(13):1449-1457.
    • (1994) Arch Intern Med , vol.154 , Issue.13 , pp. 1449-1457
  • 46
    • 0027505093 scopus 로고
    • Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
    • EAFT (European Atrial Fibrillation Trial) Study Group
    • Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet . 1993;342(8882):1255-1262.
    • (1993) Lancet , vol.342 , Issue.8882 , pp. 1255-1262
  • 47
    • 78349313002 scopus 로고    scopus 로고
    • Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the re-ly trial
    • Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol . 2010;9(12):1157-1163.
    • (2010) Lancet Neurol , vol.9 , Issue.12 , pp. 1157-1163
    • Diener, H.C.1    Connolly, S.J.2    Ezekowitz, M.D.3
  • 48
    • 77957699729 scopus 로고    scopus 로고
    • Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the european society of cardiology (esc
    • Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J . 2010;31(19):2369-2429.
    • (2010) Eur Heart J , vol.31 , Issue.19 , pp. 2369-2429
    • Camm, A.J.1    Kirchhof, P.2    Lip, G.Y.3
  • 49
    • 78751637313 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion
    • Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation . 2011;123(2):131-136.
    • (2011) Circulation , vol.123 , Issue.2 , pp. 131-136
    • Nagarakanti, R.1    Ezekowitz, M.D.2    Oldgren, J.3
  • 50
    • 79953836474 scopus 로고    scopus 로고
    • Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): A randomised, double-blind, noninferiority trial
    • Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, noninferiority trial. Thromb Haemost . 2010;105(4):721-729.
    • (2010) Thromb Haemost , vol.105 , Issue.4 , pp. 721-729
    • Eriksson, B.I.1    Dahl, O.E.2    Huo, M.H.3
  • 51
    • 35449007749 scopus 로고    scopus 로고
    • Oral dabigatran etexilate vs. Subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The re-model randomized trial
    • Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost . 2007;5(11):2178-2185.
    • (2007) J Thromb Haemost , vol.5 , Issue.11 , pp. 2178-2185
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 52
    • 34548575058 scopus 로고    scopus 로고
    • Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
    • Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet . 2007;370(9591):949-956.
    • (2007) Lancet , vol.370 , Issue.9591 , pp. 949-956
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 53
    • 57649123692 scopus 로고    scopus 로고
    • Oral thrombin inhibitor dabigatran etexilate vs north american enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    • Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty . 2009;24(1):1-9.
    • (2009) J Arthroplasty , vol.24 , Issue.1 , pp. 1-9
    • Ginsberg, J.S.1    Davidson, B.L.2    Comp, P.C.3
  • 54
    • 17444396697 scopus 로고    scopus 로고
    • Hepatic findings in long-term clinical trials of ximelagatran
    • Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf . 2005;28(4):351-370.
    • (2005) Drug Saf , vol.28 , Issue.4 , pp. 351-370
    • Lee, W.M.1    Larrey, D.2    Olsson, R.3
  • 55
    • 0642281257 scopus 로고    scopus 로고
    • Protocol for birmingham atrial fibrillation treatment of the aged study (bafta): A randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [isrctn89345269]
    • Mant JW, Richards SH, Hobbs FD, et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord . 2003;3:9.
    • (2003) BMC Cardiovasc Disord , vol.3 , pp. 9
    • Mant, J.W.1    Richards, S.H.2    Hobbs, F.D.3
  • 56
    • 0031967392 scopus 로고    scopus 로고
    • Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation
    • Marine JE, Goldhaber SZ. Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation. Chest . 1998;113(4):1115-1118.
    • (1998) Chest , vol.113 , Issue.4 , pp. 1115-1118
    • Marine, J.E.1    Goldhaber, S.Z.2
  • 57
    • 0037817710 scopus 로고    scopus 로고
    • Anticoagulant-related bleeding in older persons with atrial fibrillation: Physicians' fears often unfounded
    • Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med . 2003;163(13):1580-1586.
    • (2003) Arch Intern Med , vol.163 , Issue.13 , pp. 1580-1586
    • Man-Son-Hing, M.1    Laupacis, A.2
  • 58
    • 79958126202 scopus 로고    scopus 로고
    • Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (re-ly) trial
    • Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation . 2011;123(21):2363-2372.
    • (2011) Circulation , vol.123 , Issue.21 , pp. 2363-2372
    • Eikelboom, J.W.1    Wallentin, L.2    Connolly, S.J.3
  • 59
    • 79957715797 scopus 로고    scopus 로고
    • Anticoagulant options-Why the fda approved a higher but not a lower dose of dabigatran
    • Beasley BN, Unger EF, Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med . 2011;364(19):1788-1790.
    • (2011) N Engl J Med , vol.364 , Issue.19 , pp. 1788-1790
    • Beasley, B.N.1    Unger, E.F.2    Temple, R.3
  • 60
    • 64349107688 scopus 로고    scopus 로고
    • Rationale and design of re-ly: Randomized evaluation of long-term anticoagulant therapy warfarin compared with dabigatran
    • e801-e802
    • Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J . 2009;157(5):805-810, e801-e802.
    • (2009) Am Heart J , vol.157 , Issue.5 , pp. 805-810
    • Ezekowitz, M.D.1    Connolly, S.2    Parekh, A.3
  • 61
    • 84877848345 scopus 로고    scopus 로고
    • US Food and Drug Administration Center For Drug Evaluation And Research Accessed January 6
    • US Food and Drug Administration, Center for Drug Evaluation and Research. Other reviews for NDA 022-512: dosing in subjects with renal failure. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/022512Orig1s000OtherR. pdf. Accessed January 6, 2012.
    • (2012) Other Reviews For NDA 022-512: Dosing In Subjects With Renal Failure
  • 62
    • 83055170914 scopus 로고    scopus 로고
    • Use of dabigatran etexilate in clinical practice: Confronting challenges to improve safety and effectiveness
    • Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nurescu EA. Use of dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy . 2011;31(12):1232-1249.
    • (2011) Pharmacotherapy , vol.31 , Issue.12 , pp. 1232-1249
    • Gulseth, M.P.1    Wittkowsky, A.K.2    Fanikos, J.3    Spinler, S.A.4    Dager, W.E.5    Nurescu, E.A.6
  • 63
    • 57449098437 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment
    • Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol . 2008;48(12):1411-1419.
    • (2008) J Clin Pharmacol , vol.48 , Issue.12 , pp. 1411-1419
    • Stangier, J.1    Stahle, H.2    Rathgen, K.3    Roth, W.4    Shakeri-Nejad, K.5
  • 64
    • 77952167209 scopus 로고    scopus 로고
    • Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor
    • Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost . 2009;15(suppl 1):9S-16S.
    • (2009) Clin Appl Thromb Hemost , vol.15 , Issue.SUPPL. 1
    • Stangier, J.1    Clemens, A.2
  • 65
    • 77953158128 scopus 로고    scopus 로고
    • Measurement of the pharmacodynamic effect of dabigatran etexilate: Thrombin clotting time
    • abstract PP-TH-134
    • Stangier J, Wetzel K, Wienen W, van Ryn J, Rathgen K. Measurement of the pharmacodynamic effect of dabigatran etexilate: thrombin clotting time. J Thromb Haemost . 2009;7(suppl 2):abstract PP-TH-134.
    • (2009) J Thromb Haemost , vol.7 , Issue.SUPPL. 2
    • Stangier, J.1    Wetzel, K.2    Wienen, W.3    Van Ryn, J.4    Rathgen, K.5
  • 66
    • 45949103309 scopus 로고    scopus 로고
    • Pharmacology and management of the vitamin k antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition
    • Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest . 2008;133(6 suppl):160S-198S.
    • (2008) Chest , vol.133 , Issue.6 SUPPL.
    • Ansell, J.1    Hirsh, J.2    Hylek, E.3    Jacobson, A.4    Crowther, M.5    Palareti, G.6
  • 67
    • 80053571188 scopus 로고    scopus 로고
    • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects
    • [Epub ahead of print]
    • Erenberg ES, Kamphuisen PW, Sijpkens MK, Meijers HB, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation . 2011. [Epub ahead of print]
    • (2011) Circulation
    • Erenberg, E.S.1    Kamphuisen, P.W.2    Sijpkens, M.K.3    Meijers, H.B.4    Buller, H.R.5    Levi, M.6
  • 68
    • 80052408267 scopus 로고    scopus 로고
    • Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models
    • van Ryn J, Litzenburger T, Waterman A, et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol . 2011;57(14):E1130.
    • (2011) J Am Coll Cardiol , vol.57 , Issue.14
    • Van Ryn, J.1    Litzenburger, T.2    Waterman, A.3
  • 69
    • 78649389908 scopus 로고    scopus 로고
    • Direct and indirect costs of management of long-term warfarin therapy in canada
    • Schulman S, Anderson DR, Bungard TJ, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost . 2010;8(10):2192-2200.
    • (2010) J Thromb Haemost , vol.8 , Issue.10 , pp. 2192-2200
    • Schulman, S.1    Anderson, D.R.2    Bungard, T.J.3
  • 70
    • 77955677193 scopus 로고    scopus 로고
    • Hospitalization costs associated with warfarin-related bleeding events among older communitydwelling adults
    • Kim MM, Metlay J, Cohen A, et al. Hospitalization costs associated with warfarin-related bleeding events among older communitydwelling adults. Pharmacoepidemiol Drug Saf . 2010;19(7):731-736.
    • (2010) Pharmacoepidemiol Drug Saf , vol.19 , Issue.7 , pp. 731-736
    • Kim, M.M.1    Metlay, J.2    Cohen, A.3
  • 71
    • 84877864325 scopus 로고    scopus 로고
    • Red Book 2011. Red Book Online Edition Accessed January 6
    • Red Book 2011. Red Book Online Edition. Thomson Reuters, 2011. Accessed January 6, 2012.
    • (2012) Thomson Reuters, 2011
  • 72
    • 79551589662 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation
    • Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med . 2011;154(1):1-11.
    • (2011) Ann Intern Med , vol.154 , Issue.1 , pp. 1-11
    • Freeman, J.V.1    Zhu, R.P.2    Owens, D.K.3
  • 73
    • 79955774273 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A canadian payer perspective
    • Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost . 2011;105(5):908-919.
    • (2011) Thromb Haemost , vol.105 , Issue.5 , pp. 908-919
    • Sorensen, S.V.1    Kansal, A.R.2    Connolly, S.3
  • 74
    • 79958813704 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
    • Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation . 2011;123(22):2562-2570.
    • (2011) Circulation , vol.123 , Issue.22 , pp. 2562-2570
    • Shah, S.V.1    Gage, B.F.2
  • 75
    • 84877859991 scopus 로고    scopus 로고
    • Pradaxa (dabigatran etexilate mesylate) capsules gains preferred formulary status with AARP, nation's largest provider of Medicare Part D coverage. Ridgefield, CT (May 19, 2011). January 6
    • Pradaxa (dabigatran etexilate mesylate) capsules gains preferred formulary status with AARP, nation's largest provider of Medicare Part D coverage. Ridgefield, CT (May 19, 2011). http://www.thestreet. com/story/11125253/1/pradaxa-dabigatran-etexilate-mesylate-capsules-gains- preferred-formulary-status-with-aarp-nationslargest-provider-of-medicare-part-d- coverage.html. January 6, 2012
    • (2012)
  • 76
    • 84877847947 scopus 로고    scopus 로고
    • Pradaxa (dabigatran etexilate mesylate) capsules: special storage and handling requirements. Accessed January 6
    • Pradaxa (dabigatran etexilate mesylate) capsules: special storage and handling requirements. http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm249005.htm. Accessed January 6, 2012.
    • (2012)
  • 77
    • 84877854621 scopus 로고    scopus 로고
    • Pradaxa (dabigatran etexilate) [summary of product characteristics]. Accessed January 6
    • Pradaxa (dabigatran etexilate) [summary of product characteristics]. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000829/WC500041059.pdf. Accessed January 6, 2012.
    • (2012)
  • 78
    • 84877863967 scopus 로고    scopus 로고
    • Accessed January 6, 432169 JCP XX X 10.1177/0091270011432169 Spinler
    • New drug application submitted to FDA for rivaroxaban for prevention of stroke in patients with atrial fibrillation. Johnson &Johnson, January 5, 2011. http://www.jnj.com/connect/news/all/new-drugapplication-submitted-to-fda- for-rivaroxaban-for-prevention-ofstroke-in-patients-with-atrial-fibrillation. Accessed January 6, 2012. 432169 JCP XX X 10.1177/0091270011432169 Spinler
    • (2012)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.